An Open-Label Study to Explore the Safety, Efficacy and Pharmacokinetics of TMC207 in Japanese Patients With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)

Trial Profile

An Open-Label Study to Explore the Safety, Efficacy and Pharmacokinetics of TMC207 in Japanese Patients With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 May 2017

At a glance

  • Drugs Bedaquiline (Primary) ; Antituberculars
  • Indications Pulmonary tuberculosis
  • Focus Therapeutic Use
  • Sponsors Janssen Pharmaceutical KK
  • Most Recent Events

    • 22 Dec 2016 Planned End Date changed from 1 Nov 2018 to 1 Sep 2020.
    • 22 Dec 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Jul 2018.
    • 22 Mar 2016 Planned End Date changed from 1 Aug 2018 to 1 Nov 2018, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top